Quick Answer
EXOZYMES INC. reported R&D Expense of $3.71 million for fiscal year 2025.
EXOZYMES INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $3.71M | +98.4% |
| 2024 | $1.87M | +254.3% |
| 2023 | $527.5K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.22M | +68.2% | +51.5% |
| June 30, 2025 | $803.0K | +238.3% | +39.6% |
| March 31, 2025 | $575.0K | +107.2% | -20.5% |
| September 30, 2024 | $723.5K | +2489.8% | +204.8% |
| June 30, 2024 | $237.4K | — | -14.5% |
| March 31, 2024 | $277.6K | — | +893.6% |
| September 30, 2023 | $27.9K | — | — |
- EXOZYMES INC. showed an increase of +98.4% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2025 period, EXOZYMES INC.’s r&d expense has grown by 602.8% (from $527.5 thousand to $3.71 million).
- The most recent figure is from EXOZYMES INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: